A study evaluating effect of immunization campaign using the 4-component protein-based meningococcal vaccine (MenB-4C) in Saguenay-Lac-Saint-Jean (SLSJ) region.
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Therapeutic Use
Most Recent Events
- 09 Oct 2017 New trial record